IDM 5Alternative Names: IDM-5
Latest Information Update: 22 Feb 2010
Price : $50 *
At a glance
- Originator IDM S.A.
- Class Antineoplastics
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Breast cancer
Most Recent Events
- 08 Apr 2005 Suspended - Phase-II for Breast cancer in France (IV-injection)
- 02 Dec 2003 No development reported - Phase-II for Breast cancer in France (IV-injection)
- 30 Oct 2000 Phase-II clinical trials in Breast cancer in France (IV-injection)